The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase III results of adjuvant radiotherapy (RT) versus wait-and-see (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP)(ARO 96-02/AUO AP 09/95): Ten years follow-up.
Thomas Wiegel
No relevant relationships to disclose
Dirk Bottke
No relevant relationships to disclose
Detlef Bartkowiak
No relevant relationships to disclose
Claudia Bronner
No relevant relationships to disclose
Ursula Steiner
No relevant relationships to disclose
Alessandra Siegmann
No relevant relationships to disclose
Reinhard Golz
No relevant relationships to disclose
Stephan Störkel
No relevant relationships to disclose
Normann Willich
No relevant relationships to disclose
Axel Semjonow
No relevant relationships to disclose
Michael Stöckle
No relevant relationships to disclose
Christian Rübe
No relevant relationships to disclose
Peter Althaus
No relevant relationships to disclose
Udo Rebmann
No relevant relationships to disclose
Tilman Kälble
No relevant relationships to disclose
Horst J Feldmann
No relevant relationships to disclose
Manfred Wirth
No relevant relationships to disclose
Axel Hinke
No relevant relationships to disclose
Wolfgang Hinkelbein
No relevant relationships to disclose
Kurt Miller
No relevant relationships to disclose